MM09 - Immunotek

Drug Profile

MM09 - Immunotek

Alternative Names: Dermatophagoides farinae/Dermatophagoides pteronyssinus allergen immunotherapy - Inmunotek; House dust mite allery immunotherapy D. pteronyssinus/D. farinae - Inmunotek; M601/M 602

Latest Information Update: 23 Feb 2016

Price : $50

At a glance

  • Originator Inmunotek
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypersensitivity

Most Recent Events

  • 23 Feb 2016 Inmunotek plans a phase II trial in Rhinoconjunctivitis in Spain (SC, PO, Sublingual) (NCT02661854)
  • 03 Sep 2015 Phase-II clinical trials in Hypersensitivity in Spain (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top